Vertex Pharmaceuticals Incorporated (VRTX) has launched JOURNAVX, a breakthrough non-opioid acute pain treatment, targeting pain pathways without addiction risks. This aligns with efforts to reduce opioid use and provides a safer alternative for acute pain scenarios like post-surgical recovery. Additionally, Vertex continues to lead in cystic fibrosis therapy and gene-editing treatments for various diseases.

Read more at Yahoo Finance: Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment